

This Document is Supplementary Material to the Mask Evidence Review
 Draft Healthcare Personnel Use of N95 Respirators or Medical/ Surgical Masks for Protection Against Respiratory Infections: A Systematic Review and Meta-Analysis [PDF – 80 Pages]

<https://www.cdc.gov/hicpac/pdf/HCP-N95Mask-SLR-MainAppendix-2023-11-01-Draft-508.pdf>

Author Year	Setting	Location	Category of AE	AE Name and Definition	Surgical Masks n/N (%)	N95 Respirators n/N (%)	Measures of Association
Abdi 2022	Hospital	Iran	Physical	Dermatitis: Self-reported via questionnaire and confirmed by a dermatologist	Severity of dermatitis Very severe: 14/57 (24.56%) Severe: 7/57 (12.28%) Moderate: 11/57 (19.29%) Low: 19/57 (33.33%) None: 6/57 (10.52%)	Severity of dermatitis Very severe: 11/85 (12.94%) Severe: 20/85 (23.52%) Moderate: 12/85 (14.11%) Low: 31/85 (36.47%) None: 11/85 (12.94%)	Severity of dermatitis: p = 0.219
Aliabadi 2022	University hospital	Iran	Occupational	Vocal effort: Perceived exertion during voicing or speaking measured using the Borg CR10 scale Speech spectrum: ND Speech intelligibility: Based on speech discrimination score where the percentage of syllable intelligibility was classified as bad 0–34%; poor 34–48%; fair 48–67%; good 67–90%; and excellent 90–96%			The vocal efforts of nurses when wearing N95 face masks with the filter were increased up to severe exertion. The effect of surgical masks on reducing the transmission of speech spectrum is insignificant compared to N95. Speech intelligibility of nurses from a human speaker wearing N95 with a filter is approximately 10% lower than when using surgical mask in presence of background noise levels (p < 0.01)
Alizadeh 2022	Hospital	Iran	Physical	Skin adverse events: Skin involvement (e.g., pressure effect, erythema, itching, and burning) on the lower two-thirds of face, which includes the nose, cheek, and chin	6/20 (30.0%)	41/43 (95.3%)	p < 0.001
Alroudhan 2021	Dental	Saudi Arabia	Physical	SpO ₂ : Measured using clinical pulse oximeter before wearing mask and 1, 2, and 3 hours after wearing mask Heart rate: Measured using clinical pulse oximeter before wearing mask, and 1, 2, and 3 hours after wearing mask	SpO ₂ , before: 98.8 (SD 0.4) SpO ₂ , 1 hr after: 98.8 (SD 0.4) SpO ₂ , 2 hr after: 98.8 (SD 0.4) SpO ₂ , 3 hr after: 98.8 (SD 0.4) Heart rate, before: 79.5 (SD 8.8) Heart rate, 1 hr after: 73.1 (SD 10.0) Heart rate, 2 hr after: 81.7 (SD 7.0) Heart rate, 3 hr after: 83.8 (SD 9.3)	SpO ₂ , before: 98.2 (SD 0.7) SpO ₂ , 1 hr after: 97.0 (SD 1.1) SpO ₂ , 2 hr after: 96.6 (SD 1.2) SpO ₂ , 3 hr after: 96.2 (SE 0.9) Heart rate, before: 81.3 (SD 12.6) Heart rate, 1 hr after: 93.1 (SD 12.4) Heart rate, 2 hr after: 95.3 (SD 12.9) Heart rate, 3 hr after: 95.4 (SD 13.3)	SpO ₂ , before: p = 0.12 SpO ₂ , 1 hr after: p < 0.01 SpO ₂ , 2 hr after: p < 0.01 SpO ₂ , 3 hr after: p < 0.01 Heart rate, before: p = 0.9 Heart rate, 1 hr after: p < 0.01 Heart rate, 2 hr after: p < 0.01 Heart rate, 3 hr after: p < 0.01
Altun 2022	University hospital	Turkey	Physical	Acne: Clinical diagnosis of acne vulgaris, acne rosacea, seborrheic dermatitis, and contact dermatitis.	36/67 (53.7%)	20/34 (58.8%)	aOR: Adjusted odds ratio; model included gender, age, profession, dermatological disease history presence, weekly working hours, daily working hours, facial cleanser, mask type, and mask replacement frequency aOR: 7.45 (95% CI: 1.33–41.81), p = 0.023 aOR(backward method): 2.79 (95% CI: 1.00-7.76), p = 0.050 OR: 1.23 (95% CI: 0.53–2.84). p = 0.627
Ansari 2022	Three hospitals	Pakistan	Physical	Skin damages: HCP reported dermatological symptoms including acne, pigmentation, indentation and ear pain, itch, rash, scar at nose bridge, dry skin, and peeling skin; collected by face-to-face or telephonic interview	Dermatological symptoms unspecified: 82/212 (38.7%) Acne: 64/212 (29.2%) Pigmentation: 12/212 (5.7%) Indentation and ear pain: 110/212 (51.9%) Itch: 93/212 (43.9%) Rash: 40/212 (18.9%) Scar at nose bridge: 44/212 (20.8%) Dry skin: 50/212 (23.6%) Peeling skin: 11/212 (5.2%)	Dermatological symptoms unspecified: 86/171 (50.3%) Acne: 51/171 (29.8%) Pigmentation: 12/171 (7.0%) Indentation and ear pain: 90/171 (52.6%) Itch: 77/171 (45.0%) Rash: 47/171 (27.5%) Scar at nose bridge: 66/171 (38.6%) Dry skin: 33/171 (19.3%) Peeling skin: 16/171 (9.4%)	Dermatological symptoms unspecified: p = 0.029 Acne: p = 0.938 Pigmentation: p = 0.586 Indentation and ear pain: p = 0.885 Itch: p = 0.820 Rash: p = 0.045 Scar at nose bridge: p < 0.001 Dry skin: p = 0.311 Peeling skin: p = 0.113
Bharatha 2022	Main isolation center for COVID-19	Barbados	Physical	Adverse skin reactions: Skin reactions on cheeks, nose bridge, ear, and/or chin reported via survey	Cheeks: 18.6% Nose bridge: 16.3% Ear: 20.9% Chin: 9.3%	Cheeks: 56.4% Nose bridge: 51.3% Ear: 51.3% Chin: 33.3%	Adverse skin reactions (surgical mask is reference group): OR: 1.358 (95% CI: 0.448 - 4.4117), p = NR

Cigiloglu 2021	Hospital	Turkey	Physical	Headache: Participants were asked whether they had new-onset headaches after regular use of face masks during the pandemic period. Those with headaches were asked to indicate their duration, time of onset and severity (between 0 and 10) on the visual analog scale (VAS).	Headache: 98/224 (43.8%)	Headache: 50/87 (57.5%)	Headache: p = 0.030
Cigiloglu 2021	Hospital	Turkey	Psychological	Sleepiness: The Epworth sleepiness scale consists of eight scenarios that are measured on a scale from 0 to 3 to indicate how likely it would be for the individual to feel sleepy. The sum of each score ranges from 0 to 24 where a score higher than 10 indicates excessive daytime sleepiness	Sleepiness, mean (SD): 6.04±4.41	Filtering facepiece respirator Sleepiness, mean (SD): 8.59±5.48	Sleepiness: p < 0.001
Gelardi 2020	Two university hospitals	Italy	Occupational	Work interference: HCP were asked 'do you feel less productive?' and 'how much has your job activity got worse?' using a scale ranging from 0-10 where 0 indicates absence of any kind of alteration and 10 indicates complete alteration of the item compared to pre-COVID-19 period Reduced concentration: Evaluated using a scale ranging from 0-10 where 0 indicates the absence of reduced concentration and 10 indicates complete reduced concentration compared to pre-COVID-19 period	Work interference: Do you feel less productive? 2±2.9 How much has your job activity got worse? 3.4±2.9 Reduced concentration: 0.9±2.1	Work interference: Do you feel less productive? 0.3±1.4 How much has your job activity got worse? 5.1±3.4 Reduced concentration: 0.8±2.0	Work interference: Do you feel less productive? p < 0.0001 univariate, p = 0.039 multivariate How much has your job activity got worse? p = 0.0036 Reduced concentration: p = 0.3343
Gelardi 2020	Two university hospitals	Italy	Physical	Adverse events: HCP were asked if they had facemask-linked blurred vision, sneezing, rhinorrhea, dry nose, facial pain, itching, nausea, headache, and dizziness using a scale ranging from 0-10 where 0 indicates absence of any kind of alteration and 10 indicates complete alteration of the item compared to pre- COVID-19 period	Blurred vision: 1.05±2.3 Sneezing: 2.0±3.1 Rhinorrhea: 1.5±2.7 Dry nose: 2.4±2.7 Facial pain: 1.6±2.8 Itching: 3.7±3.6 Nausea: 0.8±2.1 Headache: 2±3.5 Dizziness: 0.7±2.1	Blurred vision: 0.4±1.5 Sneezing: 1.5±2.5 Rhinorrhea: 1.0±2 Dry nose: 2.8±3.1 Facial pain: 2.9±2.8 Itching: 2.8±2.9 Nausea: 0.1±1.0 Headache: 2.4±0.3 Dizziness: 0.1±0.06	Blurred vision: p = 0.0328 Sneezing: p = 0.1792 Rhinorrhea: p = 0.1279 Dry nose: p = 0.2388 Facial pain: p = 0.0125 univariate, p = 0.007 multivariate Itching: p = 0.0792 Nausea: p = 0.0135 Headache: p = 0.2797 Dizziness: p = 0.0173
Hajjij 2020	University hospital	Morocco	Physical	De novo headache: Reported as a headache never experienced before Aggravated headache: Reported as an aggravation of pre-existing headache	De novo: 4/7 Aggravated: 3/7	De novo: 47/148 Aggravated: 42/148	De novo: p = 0.22 Aggravated: p = 0.41
Ipek 2021	University hospital, tert	Turkey	Occupational	Concentrating difficulty: HCP answered 'yes' if observed after using mask via questionnaire Attention deficit: HCP answered 'yes' if observed after using mask via questionnaire	Concentrating difficulty: 21/34 (61.8%) Attention deficit: 5/34 (14.7%)	Concentrating difficulty: 6/34 (17.6%) Attention deficit: 17/34 (50.0%)	Concentrating difficulty: p < 0.001 Attention deficit: p < 0.001
Ipek 2021	University hospital, tert	Turkey	Psychological	Fatigue: ND Drowsiness: ND	Fatigue: 6/34 (17.6%) Drowsiness, n/N (%): 2/34 (5.9%)	Fatigue: 21/34 (61.8%) Drowsiness, n/N (%): 16/24 (47.1%)	Fatigue: p < 0.001 Drowsiness: p = 0.001

Ipek 2021	University hospital, tert	Turkey	Physical	pCO ₂ : Measured after wearing mask Headache: HCP reported via questionnaire Dizziness: HCP reported via questionnaire Respiratory distress: HCP reported via questionnaire Sweating: HCP reported via questionnaire experiencing sweating on face after mask use Facial itching: HCP reported via	pCO ₂ : 37.33 ± 8.81 Headache: 5 (14.7%) Dizziness: 2/34 (5.9%) Respiratory distress: 8 (24%) Sweating: 18 (53%) Facial itching: 8 (23.5%) Drowsiness: 2 (5.9%) Fatigue: 5 (14.7%) Difficulty breathing: 8 (23.5%)	pCO ₂ : 28.46 ± 7.77 Headache: 20 (58.8%) Dizziness: 8/34 (23.8%) Respiratory distress: 27 (80%) Sweating: 9 (27%) Facial itching: 9 (26.5%) Drowsiness: 16 (47.1%) Fatigue: 21 (61.8%) Difficulty breathing: 27 (79.4%)	pCO ₂ : p < 0.001 Headache: p = 0.001 Dizziness: p = 0.070 Respiratory distress: p = 0.001 Sweating: p = 0.022 Facial itching: p = 1.0 Drowsiness: p = 0.001 Fatigue: p < 0.001 Difficulty breathing: p = 0.001
Liu 2022	12 hospitals	China	Physical	Adverse reactions: Facemask wearing-related adverse reaction including shortness of breath, upper respiratory symptoms, damaged skin on nose, damaged facial skin, face pain, nose pain, ear pain, and eczema collected via online survey	Shortness of breath: 363/954 (38.1%) Upper respiratory symptoms: 73/954 (7.65%) Damaged skin on nose: 136/954 (14.26%) Damaged facial skin: 57/954 (5.97%) Face pain: 358/954 (37.53%) Nose pain: 217/954 (22.75%) Ear pain: 754/954 (79.04%) Eczema: 209/954 (21.91%)	Shortness of breath: 57/136 (41.9%) Upper respiratory symptoms: 16/136 (11.76%) Damaged skin on nose: 22/136 (16.18%) Damaged facial skin: 12/136 (8.82%) Face pain: 47/136 (34.56%) Nose pain: 40/136 (29.41%) Ear pain: 110/136 (80.88%) Eczema: 43/136 (31.62%)	Shortness of breath: p = 0.01 Upper respiratory symptoms: p = 0.101 Damaged skin on nose: p = 0.552 Damaged facial skin: p = 0.202 Face pain: p = 0.503 Nose pain: p = 0.088 Ear pain: p = 0.619 Eczema: p = 0.012
MacIntyre 2011	15 tertiary hospitals	China	Physical	Adverse events: Self reported headaches, rash, difficulty breathing, pressure on nose, and trouble communicating:	Medical masks Headaches: 11/281 (3.9%) Rash: 13/281 (4.6%) Difficulty breathing: 35/281 (12.5%) Pressure on nose: 31/281 (11.0%) Trouble communicating: 9/303 (3.0%)	Headaches: 94/701 (13.4%) Rash: 35/701 (5.0%) Difficulty breathing: 136/701 (19.4%) Pressure on nose: 366/701 (52.2%) Trouble communicating: 62/775 (8.0%)	Headaches: p < 0.01 Rash: p = 0.81 Difficulty breathing: p = 0.01 Pressure on nose: p < 0.01 Trouble communicating: p < 0.01
Manerkar 2021	Tertiary care dental clin	India	Physical	Headache: Mask-associated symptom of psychological stress collected by self-administered questionnaire Oxygen saturation (SaO ₂): Measured using pulse oximeter and collected in morning Heart rate: Measured using pulse oximeter and collected in morning	Headache: 31/59 (52.5%) Oxygen saturation: Baseline: 98.29±1.36 60 min: 98.14±1.16 120 min: 98.17±1.04 Pulse rate: Baseline: 83.54±11.83 60 min: 84.97±14.25 120 min: 82.78±11.42	Headache: 52/69 (75.4%) Oxygen saturation: Baseline: 98.3±0.97 60 min: 96.13±2.84 120 min: 97.61±1.99 Pulse rate: Baseline: 85±12.8 60 min: 83.25±14.13 120 min: 84.01±14.57	Headache: OR: 6.685 (95% CI: 2.45-19.18), p < 0.05 Oxygen saturation: Baseline: p = 0.582 60 min: p = 0.001 120 min: p = 0.012 Pulse rate: Baseline: p = 0.537 60 min: p = 0.522 120 min: p = 0.663
Maniaci 2021	University hospital	Italy	Physical	Eye symptoms: HCP reported symptoms including itching, tearing, or redness of the eyes on Likert scale via questionnaire Nasal symptoms: HCP reported symptoms on Likert scale via questionnaire Pulmonary disorders: HCP reported lower respiratory tract symptoms on Likert scale via questionnaire			Eye symptoms: No differences emerged for the type of mask (surgical, FFP1, FFP2, or FFP3) used regarding the prevalence of eye symptoms (p > 0.05) Nasal symptoms: There was a higher association between type of device (FFP2 or FFP3 mask) used and nasal symptoms (p = 0.001). Pulmonary disorders: HCP using FFP2 or FFP3 masks reported higher percentages of pulmonary disorders (p = 0.002)

Nwosu 2021	Hospitals	Nigeria	Physical	<p>Difficulty breathing: Difficulty in breathing reported during interview contributed to discomfort Skin irritation: Facial irritation/hotness reported during interview contributed to discomfort</p> <p>SpO2: Pulse oximeter with probe applied to the index finger was used for non-invasive determination of arterial oxygen saturation checked before donning facemask and then repeated before mask removal</p>	<p>Difficulty breathing: 16/48 (33.3%) Skin irritation: 19/48 (39.6%)</p> <p>SpO2: Pre-test mean (SD): 98.1 (0.8) Post-test mean (SD): (98.1) (0.8)</p>	<p>Difficulty breathing: 12/28 (42.9%) Skin irritation: 14/28 (50%)</p> <p>SpO2: Pre-test mean (SD): 97.9 (0.8) Post-test mean (SD): 97.8 (0.8)</p>	<p>Difficulty breathing: p = 0.406 Skin irritation: p = 0.377</p> <p>SpO2 Pre-test: p = 0.388 Post-test: p = 0.114</p>
Nwosu 2021	Hospitals	Nigeria	Occupational	<p>Difficulty in communication: Communication difficulty with team members reported during interview contributed to mask discomfort</p>	<p>Difficulty in communication: 23/48 (47.9%)</p>	<p>Difficulty in communication: 13/28 (46.4%)</p>	<p>Difficulty in communication: p = 0.9</p>
Park 2021	Teaching hospital	Korea	Physical	<p>Skin lesions: Acne, rash, or scales caused by facial masks reported via self-administered online survey conducted through hospital intranet system</p> <p>Skin symptoms: Itching, dryness/tightness, stinging sensation, and flushing caused by facial masks reported via self-administered online survey conducted through hospital intranet system</p>	<p>Skin lesions: 71/131 (54.2%) Skin symptoms: 84/131 (64.1%)</p>	<p>N95: Skin lesions: 13/21 (61.9%) Skin symptoms: 15/21 (71.4%)</p> <p>KF94: Skin lesions: 96/151 (63.6%) Skin symptoms: 108/151 (71.5%)</p>	<p>OR: Odds ratio</p> <p>N95 vs. surgical (ref): Skin lesions, OR: 1.294 (95% CI: 0.487 - 3.435) Skin symptoms, OR: 1.243 (95% CI: 0.430 - 3.695)</p> <p>KF94 vs. surgical (ref): Skin lesions, OR: 1.609 (95% CI: 0.974 - 2.657) Skin symptoms, OR: 1.657 (95% CI: 0.962 - 2.852)</p>
Peres 2022	Healthcare organization	Portugal	Physical	<p>Discomfort: PPE use associated with HCP reporting discomfort Dyspnea: PPE use associated with HCP reporting dyspnea Skin rash or itching: PPE use associated with HCP reporting skin rash or itching Headache: PPE use associated with HCP reporting headache</p>	<p>Discomfort: 26.8% Dyspnea: 14.4% Skin rash or itching: 19.4% Headache: 19.4%</p>	<p>Discomfort: 58.2% Dyspnea: 36.0% Skin rash or itching: 37.5% Headache: 37.5%</p>	<p>Discomfort: p < 0.001 Dyspnea: p < 0.001 Skin rash or itching: p < 0.001 Headache: p < 0.001</p>
Peres 2022	Healthcare organization	Portugal	Occupational	<p>Task performance: HCP reported PPE use was negatively associated with task performance Communication: HCP reported PPE use was negatively associated with communication</p>	<p>Task performance: 18.9% Communication: 40.9%</p>	<p>Task performance: 41.5% Communication: 55.0%</p>	<p>Task performance: p < 0.001 Communication: p < 0.001</p>
Ramirez-Moreno 2020	Tertiary hospital	Spain	Physical	<p>De novo headache: When a new headache occurs for the first time in close temporal relationship to use PPE, even when the headache has the characteristics of a primary headache (migraine, tension type of headache, cluster headache or one of the other trigeminal autonomic headaches)</p>			<p>aOR: Adjusted odds ratio; model adjusts for HCP type and asthma OR: Odds ratio</p> <p>aOR: 2.14 (95% CI: 1.07 - 4.32), p = 0.027 OR: 2.08 (95% CI: 1.07 - 4.07), p = 0.026</p>

Rapisarda 2021	Hospitals and clinics	Italy	Physical	Headache: Headache outcome measures included headache days, migraine days, migraine-like days, average headache severity, headache-related disability collected using headache impact test, and allodynia scored using the allodynia symptom checklist			Type of facemask was not associated with change in headache outcome measures from baseline among HCP with predisposed headaches and HCP with no history of headaches ($p > 0.05$).
Su 2021	Tertiary center	Taiwan	Physical	Vital signs: Change in SpO ₂ , PaO ₂ , PCO ₂ , systolic and diastolic blood pressure, and heart rate from baseline to after 8 hours of wearing facemasks, measured using a fingertip detector Shortness of breath: Shortness of breath after wearing facemasks was evaluated after questionnaire Headache: Headache after wearing facemasks was evaluated via questionnaire Dizziness: Dizziness after wearing facemasks was evaluated via questionnaire	Vital signs, change from baseline: SpO ₂ : -0.02 (SE 0.03) PaO ₂ : -0.29 (SE 0.28) PCO ₂ : 0.03 (SE 0.06) Systolic BP: -0.43 (SE 0.39) Diastolic BP: -0.41 (SE 0.26) Heart rate: 0.63 (SE 0.58) Shortness of breath: 1/34 (3%) Headache: 0/34 (0%) Dizziness: 0/34 (0%)	Vital signs, change from baseline: SpO ₂ : 0.03 (SE 0.04) PaO ₂ : 0.42 (SE 0.34) PCO ₂ : -0.06 (SE 0.07) Systolic BP: -0.78 (SE 0.34) Diastolic BP: -0.49 (SE 0.29) Heart rate: -1.39 (SE 0.53) Shortness of breath: 15/34 (44%) Headache: 6/34 (18%) Dizziness: 5/34 (15%)	Adjusted difference of least square means: SpO ₂ : 0.06 (95% CI: -0.04 - 0.15), $p = 0.2454$ PaO ₂ : 0.71 (95% CI: -0.16 - 1.58), $p = 0.1090$ PCO ₂ : -0.10 (95% CI: -0.27 - 0.07), $p = 0.2674$ Systolic BP: -0.35 (95% CI: -1.36 - 0.67), $p = 0.5034$ Diastolic BP: -0.09 (95% CI: -0.84 - 0.67), $p = 0.8249$ Heart rate: -2.01 (95% CI: -3.56 - -0.47), $p = 0.0105$ Shortness of breath: $p < 0.001$ Headache: $p = 0.012$ Dizziness: $p = 0.027$
Su 2021	Tertiary center	Taiwan	Psychological	Fatigue: Reported after wearing facemasks and evaluated via questionnaire	Fatigue: 0/34 (0%)	Fatigue: 9/34 (27%)	Fatigue: $p = 0.001$
Su 2021	Tertiary center	Taiwan	Occupational	Difficulty talking: Symptom after wearing facemasks was evaluated via questionnaire	0/34 (0%)	18/34 (53%)	$p < 0.001$
Tatti 2022	Academic hospital	Italy	Physical	Best-corrected visual acuity (BCVA): Measured by using a 3-m Snellen chart and then converted to LogMAR Corneal fluorescein staining (FS): Evaluated according to the Oxford Grading Scale on the basis of the fluorescein dye staining pattern on an ocular surface Tear film break-up time (BUT): Timespan, after fluorescein dye application, between a complete blink and the appearance of the first dry spot on the corneal surface; considered pathological when < 10 s Schirmer test I: Length of wetting from notch of paper strip after 5 min with eyes gently closed; considered pathological when < 10 mm / 5 min	BCVA, pre shift: 0.06 (SE 0.01) BCVA, post shift: 0.07 (SE 0.01) FS, pre shift: 0.01 (SE 0.04) FS, post shift: 0.43 (SE 0.07) BUT, pre shift: 8.86 (SE 0.28) BUT, post shift: 7.06 (SE 0.25) Schirmer, pre shift: 16.14 (SE 0.94) Schirmer, post shift: 13.05 (SE 1.02)	BCVA, pre shift: 0.04 (SE 0.01) BCVA, post shift: 0.06 (SE 0.01) FS, pre shift: 0.01 (SE 0.03) FS, post shift: 0.55 (SE 0.06) BUT, pre shift: 9.34 (SE 0.26) BUT, post shift: 7.78 (SE 0.24) Schirmer, pre shift: 16.18 (SE 0.85) Schirmer, post shift: 14.70 (SE 0.92)	No significant difference between surgical masks and N95s were observed ($p > 0.05$). BCVA: $p = 0.41$ FS: $p = 0.96$ BUT: $p = 0.111$ Schirmer: $p = 0.49$

Score	Color	Definition
1		Element is present in this study
NA		Element is not applicable to this study design
0		Unclear if this element is present in this study
-1		Element is not present in this study

Figure S1: Funnel Plot for the studies included in the primary analysis for Seasonal Pathogens




Figure S2: Funnel Plot for the studies included in the primary analysis for Novel Pathogens




Figure S3: Funnel Plot for the studies included in Sensitivity Analysis A for Novel Pathogens




Figure S4: Funnel Plot for the studies included in Sensitivity Analysis B for Novel Pathogens

